1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Global Analysis of Ebola Disease : Expenditure on Prevention and Containment to Soar towards $5.9 Billion by End of 2016

Key Findings

•The Ebola virus is being contained in many of the developed nations such as the United States, Spain, and France due to better infrastructure and the availability of rapid tests and quality treatment.
•The porous borders of Western Africa and its neighboring countries still pose the threat of a global Ebola epidemic.
•China and India pose the most risk because of their large stakes in Africa, and due to increasing trade interactions and open sea ports, the threat of Ebola transmission in these countries is high.
•Frost & Sullivan’s optimistic prediction foresees a decrease in the number of Ebola cases globally in late 2015 through early 2016 due to the commercial availability of approved vaccines and treatment in the hard-hit nations of Africa.
•The containment of the disease is impeded by lack of healthcare workers and availability of treatment.
•The urgent demand for sensitive and rapid tests in detecting and containing this disease will spur the molecular methods market.
•The immunodiagnostics market will also continue to grow due to its cost effectiveness, especially for initial screening of Ebola.
•Frost & Sullivan predicts that if the Ebola crisis is not contained, despite best efforts, the global burden will reach $xx billion by the end of 2016.

What is Ebola?

•Ebola virus disease, also known as Ebola hemorrhagic fever, has threatened humanity since its initial occurrence in 1976. It is often severe and fatal in humans.
•The virus was initially transmitted from animals, such as bats, to humans.
•According to the World Health organization (WHO), the disease spreads among people when one comes in contact with an infected person’s bodily fluids (e.g., blood and secretions such as saliva and sweat). Infection also occurs by indirect contact with these fluids, meaning this disease can be spread by surfaces and materials (e.g., bedding, clothing) contaminated by these fluids. The current 2014 outbreak has been the largest and most complex since 1976.
•The reason Ebola is such a hard disease to diagnose and treat is because the virus changes the RNA in our cells and replicates unique to individuals.
•The disease is not infectious until the onset of symptoms, which has an incubation period of xx to xx days.
•Initial symptoms include: fever, fatigue, muscle pain, headache, and sore throat.
•Later stage symptoms include: vomiting, diarrhea, rash, symptoms of impaired kidney and liver function, and, in some cases, both internal and external bleeding.
•No proven standardized treatment for this disease currently exist.
•Three main vaccines are in the pipeline developed by GlaxoSmithKline, Johnson & Johnson, and New Link Genetics Corporation to enable containment and preventative measures.

Key Questions This Study Will Answer

What is the outlook for the Ebola diagnostics market ?
What are the key predictions for new Ebola cases and the associated burden in 2015 and 2016?
What are some of the diagnostic products and drug/vaccines in the pipeline to help contain this disease?
What is the potential global expenditure due to the prevalence of Ebola?

CEO’s Perspective

GlaxoSmithKline appears at the forefront of vaccine development and will be the market leader by mid-2015.
Corgenix will dominate the Ebola diagnostics market due to rapid TAT after its launch in 2015, provided the disease prevails.
More immunodiagnostics kits will be sold due to their cost effectiveness, especially in developing nations.
If Ebola is transmitted to East Asia, the global market in 2015 for molecular methods and immunodiagnostics will reach $xx million and $xx million respectively.

Table Of Contents

Global Analysis of Ebola Disease : Expenditure on Prevention and Containment to Soar towards $5.9 Billion by End of 2016
Executive Summary
Market Overview
Competitive Landscape
Companies to Watch
Frost and Sullivan Story

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

  • $ 59500
  • Industry report
  • January 2017
  • by Venture Planning Group

This unique 68-country survey from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well ...

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.